We next evaluated the effects of DAC and RG2833 on the expression of CDKN2A. It has been shown in other cancers that demethylation at the CDKN2A promoter can reverse the downregulation commonly seen in cancers lacking CDKN2A deletion [8, 35]. Here, CDKN2A is linked to cancer.